MiNDERA Corp.
Non-invasive molecular testing for skin cancer
Executive Summary
MiNDERA Corp. is developing an alternative to punch biopsies for diagnosing skin cancer: its microneedle device extracts biomarkers from the skin in a procedure that the start-up says is highly accurate and cost-effective for office-based diagnostic applications in dermatology.
You may also be interested in...
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.
Structure Emerges In Obesity Race With Oral GLP-1 Agonist
Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.